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A B S T R A C T
Background: Comparisons of different staphylococci in orthopedic implant infections have rarely been
reported. In this study we assessed total joint arthroplasty infections and other orthopedic implant
infections due tomethicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus
aureus (MRSA), and coagulase-negative staphylococci (CoNS).
Methods: This was a retrospective study performed at the Geneva University Hospitals for the period
January 1996 to June 2008.
Results: There were 44 infections due to MRSA, 58 due to MSSA, and 61 due to CoNS. Overall cure was
achieved in 57% (25/44) of MRSA infections, 72% (42/58) of MSSA infections, and 82% (50/61) of CoNS
infections, after aminimum follow-up of 1 year. In the subgroup of arthroplasty infections only, cure was
achieved in 39% (7/18) of MRSA, 60% (15/25) of MSSA, and 77% (30/39) of CoNS episodes. In multivariate
analysis, arthroplasty (odds ratio (OR) 0.2, 95% conﬁdence interval (95% CI) 0.1–0.6) andMRSA infections
(OR 0.3, 95% CI 0.1–0.9) were inversely associated with overall cure for all implants. CoNS infection (OR
3.0, 95% CI 1.2–8.0) and the insertion of a new implant (OR 4.5, 95% CI 1.6–13.1) were associated with
higher cure results. Methicillin resistance, immunosuppression, sex, age, duration of antibiotic therapy,
one-stage revision, rifampin use, and total number of surgical interventions did not inﬂuence cure.
MRSA-infected patients had more post-infection sequelae than patients with MSSA or CoNS (Chi-square
test 13/44 vs. 93/119, OR 3.4, 95% CI 1.3–8.9, p = 0.004).
Conclusions: In orthopedic implant infections, S. aureus is more virulent than CoNS. MRSA has the worst
outcome and CoNS the best.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Staphylococci comprise up to two-thirds of all pathogens in
orthopedic implant infections;1,2 these infections are difﬁcult to
treat because of the ability of the organisms to form small-colony
variants3 and to grow into bioﬁlms.4 Additionally, foreign material
itself inhibits neutrophil antibacterial activity.5,6
Methicillin-resistant staphylococcal species may adversely
inﬂuence treatment outcome, as has previously been shown for
staphylococcal bacteraemia7,8 and for implant infections.9,10
Comparative studies regarding the epidemiology and outcomes
of localized orthopedic implant-related infections stratiﬁed by
staphylococci or type of orthopedic implant are rare. Clinical§ Presented in part as a poster at the Annual Meeting of the Swiss Society for
Infectious Diseases, June 2009, Geneva and the Annual Congress of the European
Society for Surgical Research, June 2010, Geneva.
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doi:10.1016/j.ijid.2010.05.014experience suggests that methicillin-resistant infections might
have more recurrences and more sequelae than methicillin-
sensitive infections.
The objective of this study was to assess the clinical features
and outcome in patients with orthopedic implant infections (total
joint arthroplasties and fracture ﬁxation devices) due to the three
main groups of staphylococci: methicillin-resistant Staphylococcus
aureus (MRSA),methicillin-sensitive Staphylococcus aureus (MSSA),
and coagulase-negative staphylococci (CoNS). In a second step, we
assessed risk factors for recurrent disease for implant infections




The Geneva University Hospitals form a 2200-bed tertiary
hospital with a high MRSA endemicity (30% of all clinical S. aureus
isolates);11 sequence type 228 is the predominant MRSA strain.ses. Published by Elsevier Ltd. All rights reserved.
D. Teterycz et al. / International Journal of Infectious Diseases 14 (2010) e913–e918e914The Orthopedic Surgical Service has 119 acute care beds and a
dedicated infectious diseases specialist; 5374 surgical procedures
were performed here in 2007. This service has run a cohort for total
joint arthroplasties since 1996.12
2.2. Data collection
Databases from the Laboratory of Bacteriology, the Geneva
Arthroplasty Registry,12 the Septic Orthopedic Cohort, and the
hospital’s administrative coding were retrospectively searched for
staphylococcal infections related to orthopedic implants for the
period January 1996 to June 2008. Sixty variables for each episode
were assessed with information pertaining to demographic
characteristics, microbiology, treatmentmodalities, and outcomes.
A surgeon and a physician independently recorded each variable
on a spreadsheet for analysis. In the case of discordance, a
consensus was obtained by involving a third co-author. Patients
were followed-up to 30 September 2009. A minimum follow-up
time of 1 year after the end of treatment was required for study
inclusion.
2.3. Microbiological procedures
The microbiological procedures were unchanged during the
study period and based on the Clinical and Laboratory Standards
Institute (CLSI) guidelines.13 In order to enhance speciﬁcity, only
cultures that were grown on plates were considered. Staphylococci
were characterized to the species level by slidex agglutination
(Pastorex1, Bio-Rad), DNAse tests (homemade), the ID32 Staphy-
lococcus Gallery (bioMe´rieux, Marcy l’Etoile, France), and/or the
Vitek ID system. The staphylococci were interpreted as the same if
surrogate markers such as species, staphylococcal chromosomal
cassettes (SCC), presence of exfoliatins A and B, Panton–Valentine
leukocidin, toxic shock syndrome toxins and agr gene regulator
genes, and antibiotic susceptibility patterns were identical. No
typing was performed. Since clinical specimens had not been
stored, no retrospective analyses of minimal inhibitory concentra-
tions, e.g., for vancomycin against MRSA, could be performed.
2.4. Deﬁnitions
Inclusion criteria were: the presence of an implant; local signs
of infection such as heat, erythema, pus, or functional impairment;
a medical report; a targeted antibiotic treatment; and the presence
of the same Staphylococcus sp in more than one intraoperative
sample.
Exclusion criteria were: antibiotic medication in the preceding
four weeks (to avoid a potential bias by ‘selection’ of methicillin-
resistant strains in microbiological samplings that might have
been pre-treated with beta-lactam antibiotics, thus hiding other
susceptible pathogens); an active follow-up shorter than 3months
after the end of treatment; and infections occurring after spinal
surgery. Co-pathogenswere accepted only if the Staphylococcus spp
outnumbered them by at least three-fold in intraoperative
microbiological specimens.
Since infections of total joint arthroplasties might be different
from those following other orthopedic implant procedures, all
analyses were repeated for arthroplasty infections and fracture
ﬁxation devices separately. Arthroplasties were deﬁned as total
hip, total knee, and total ankle prostheses. The fracture ﬁxation
device group encompassed intramedullary nails, plates/screws,
screws alone, external ﬁxation, wires, and pins.
Cure was deﬁned as complete clinical and microbiological
resolution of the former infection after a minimum follow-up time
of 1 year following the end of treatment. This follow-upwas active,
e.g., regular postoperative controls. There was also a passivefollow-up by analysis of patient medical records during the last
visit to theGenevaUniversity Hospitals, independent of orthopedic
reasons. This passive follow-up had no upper time limit, unless
there was general censoring on 30 September 2009, the date of
closure for data sampling. Recurrence of infection meant new
clinical signs of infection with the same microorganism at least 2
weeks after the end of treatment for the ﬁrst episode. A
pseudarthrosis without proof of the formerly infecting Staphylo-
coccus spp according to study deﬁnitions was interpreted as
sequelae, but not as recurrent infection. The duration and
modalities of antibiotic treatment concomitant to surgery were
undertaken according to expert opinion.5
2.5. Statistical analyses
Comparisons of the groups of staphylococcal infections were
performed using the Pearson Chi-square test, Fisher’s exact test, or
the Wilcoxon rank sum test, as appropriate. Logistic regression
analyses determined associationswith cure. Independent variables
with a p-value of 0.2 in univariate analysis were added stepwise
in the multivariate analysis. The following variables were
introduced into the ﬁnal model independently of their association
in univariate analysis: sex, age, duration of antibiotic treatment,
number of surgical interventions, and methicillin resistance. All
variables were checked for confounding, collinearity, and interac-
tion; the latter by Mantel–Haenszel estimates. p-Values of 0.05
(two-tailed) were considered signiﬁcant. STATA software (v. 9.0;
STATA Corp., USA) was used.
3. Results
3.1. Patient populations
A total of 205 episodes of staphylococcal orthopedic implant
infection were retrieved. Of these, 42 were excluded due to:
follow-up shorter than 3 months or lost to follow-up (n = 32);
substantial co-infection with Pseudomonas aeruginosa (n = 2),
Enterobacter cloacae (n = 2), Escherichia coli (n = 1), Propionibacter-
ium acnes and Streptococcus constellatus (n = 1), and Enterococcus
faecalis (n = 1); infection of spondylodesis material (n = 2). One
schizophrenic patient with MSSA infection was excluded because
of very poor compliance.
In the ﬁnal evaluation, a total of 163 primary surgical site
infections in 157 patients (73 females; median age 69 years,
interquartile range (IQR) 50–80 years) underwent further analysis.
The median follow-up time was 2.3 years (IQR 1.1–4.3 years).
3.2. Implants
The infected implants in the arthroplasty group included total
hip (n = 52), total knee (n = 29), and total ankle (n = 1). In the
fracture ﬁxation devices group, the infected implants included
plates/screws (n = 40), intramedullary nails (n = 16), external
ﬁxation (n = 13), hip screws (n = 4), other screws (n = 4), patellar
cerclage wire (n = 3), and pins (n = 1).
3.3. Staphylococci
There were 44 episodes due to MRSA, 58 due to MSSA, and 61
due to CoNS. Community-acquired MRSA was not encountered.14
The species of CoNS were Staphylococcus epidermidis (n = 36),
Staphylococcus lugdunensis (n = 3), Staphylococcus capitis (n = 2),
Staphylococcus hominis (n = 2), and one episode each of Staphylo-
coccus intermedius, Staphylococcus simulans, Staphylococcus xylosus
and Staphylococcus schleiferi. The CoNS were not further identiﬁed
to the species level for 14 episodes.
Table 1
Characteristics and comparisons between three groups of staphylococcal orthopedic implant-associated infections












Female sex 23 (52%) 23 (40%) 29 (48%)
Median age 74 years 0.003a 60 years 0.001a 71 years
Chronic immunosuppressionb 11 (25%) 14 (24%) 17 (28%)
Infection
Median time delay between previous implantation and infection onset 21 days 0.001a 125 days 129 days
Bacteremia 9 (20%) 19 (33%) 0.000a 0 (0%)
Treatment
Median duration of antibiotics 10 weeks 6 weeks 9 weeks
Use of rifampin 20 (45%) 32 (55%) 39 (64%)
Median No. of surgical interventions 2 2 1
Removal of infected implant 29 (66%) 46 (79%) 46 (75%)
Re-implantation of a new implant 9 (20%) 13 (22%) 0.017a 27 (44%)
Outcomes
Recurrence of infection 5 (11%) 9 (16%) 6 (10%)
Cure 25 (57%) 42 (72%) 50 (82%)
Median length of hospital stay 57 days 0.026a 29 days 39 days
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; CoNS, coagulase-negative staphylococci.
Group comparisons were performed with the Wilcoxon rank sum test, Fisher’s exact test, or the Pearson Chi-square test, as appropriate.
a Only statistically signiﬁcant p-values of 0.05 (two-tailed) are displayed.
b Diabetesmellitus, transplantation, chronicalcoholism,neoplasia, Child’s class Ccirrhosis,AIDS, steroidmedication. Polytraumadidnot countas chronic immunosuppression.
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methicillin-resistant. Three staphylococci (all CoNS)were resistant
to rifampin. Five MSSA patients, four MRSA patients, and two
patients with CoNS were co-infected with other pathogens, with
the Staphylococcus spp outnumbering these by at least three-fold in
microbiological specimens; pathogens included Klebsiella pneu-
moniae (n = 2), Proteus mirabilis (n = 2), CoNS (n = 2), and one case
each of Enterococcus faecalis, Streptococcus pyogenes, MRSA,
Streptococcus constellatus, and Enterobacter cloacae.
3.4. Clinical presentation of all implant infections
Table 1 summarizes the differences in clinical presentation
among the three groups of staphylococci for all types of implant
infections. Statistically signiﬁcant differences included the follow-
ing: MRSA infections had shorter incubation times; patients with
MSSA infections were younger than patients with methicillin-
resistant staphylococci; and bacteremia was witnessed only in S.
aureus (MRSA and MSSA), but not in CoNS infections.
3.5. Treatment
Allpatients receivedsystemicantibiotic therapydirected towards
the causative pathogen for a median duration of 7 weeks (IQR 6–12
weeks). There were no signiﬁcant differences in duration of
treatment between the staphylococcal groups (Table 1) or between
arthroplasty and fracture ﬁxation device infections (8 vs. 7 weeks,
p = 0.21). Therewere no clear preferences for the choice of antibiotic
agents.MRSA and CoNSwere treatedwith vancomycin, doxycycline,
and combinations of ciproﬂoxacin–rifampin or fusidic acid–rifam-
pin. For MSSA, clindamycin, vancomycin, ﬂoxacillin, rifampin, and
ciproﬂoxacin were used in the majority of cases. In 91 infections
(56%, 91/163), rifampin was used in combination therapy.
All but two patients underwent surgery, and the median
number of interventions to cure was two (IQR 1–2). There were no
signiﬁcant differences in terms of number of surgical interventions
between the staphylococcal groups or between the groups of
arthroplasty vs. fracture ﬁxation device infections (median
number two vs. two interventions, p = 0.65). In contrast, a revision
arthroplastywasmore frequently performed in patientswith CoNS
infections than those with S. aureus infections (Table 1).3.6. Overall outcomes for all implant infections
Two patients died of septic shock due to MSSA and MRSA,
respectively. They were not included in the ﬁnal analysis as they
were among the 32 patients excluded because of insufﬁcient
follow-up time.
Among the remaining 163 infections, cure was achieved in 57%
(25/44) of all episodes of MRSA, in 72% (42/58) of MSSA, and in 82%
(50/61) of CoNS (Table 1). These differences were not statistically
signiﬁcant. Forty-three patients (27%, 43/157) had sequelae of
former infection, including: Girdlestone hip (n = 8), arthrodesis
(n = 8), amputation (n = 4), and other functional handicaps and/or
incapacitating pain (n = 23). MRSA-infected patients had signiﬁ-
cantly more sequelae than MSSA or CoNS patients (13/44 vs. 93/
119, odds ratio (OR) 3.4, 95% conﬁdence interval (95% CI) 1.3–8.9,
p = 0.004).
Recurrence of infection always occurred locally andwas seen in
20 episodes (12%, 20/163) with a median delay of 94 days after the
end of treatment. The number of recurrences were not statistically
different between arthroplasty vs. fracture ﬁxation device infec-
tions (12 vs. 8 recurrences, p = 0.36).
The median length of hospital stay for all staphylococcal
infectionswas 36 days (IQR 16–82 days). Patientswithmethicillin-
resistant infections (MRSA and resistant CoNS) stayed signiﬁcantly
longer (Table 1).
3.7. Subgroups of patients
Upon stratiﬁcation of the results into the staphylococcal groups,
for arthroplasty infection, curewas achieved in 39% (7/18) ofMRSA
episodes, in 60% (15/25) of MSSA episodes, and in 77% (30/39) of
CoNS episodes. These differences were statistically signiﬁcant
(Pearson Chi-square test between MRSA and CoNS, p = 0.008).
Patients with arthroplasty infections (n = 82, 50%) were signiﬁ-
cantly older than those with fracture ﬁxation device infections
(n = 81, 50%; median age 73 vs. 55 years, p < 0.001), were more
immunosuppressed (28/82 vs. 14/81, p = 0.014), had a longer
incubation time (median delay 176 vs. 50 days, p < 0.034), had
signiﬁcantly lower cure rates (52/82 vs. 65/81, p = 0.017), a
signiﬁcantly shorter recurrence time to infection (median delay 71
Table 2
Characteristics and comparisons between three groups of staphylococcal arthroplasty infections












Female sex 11 (61%) 9 (36%) 19 (49%)
Median age 80 years 0.043a 71 years 71 years
ASA score of 1 0 (0%) 2 (13%) 3 (11%)
ASA score of 2 5 (50%) 11 (69%) 13 (48%)
ASA score of 3 5 (50%) 3 (19%) 11 (41%)
Chronic immunosuppressionb 7 (39%) 8 (32%) 13 (33%)
Infection
Median time delay between previous implantation and infection onset 16 days 0.001a 361 days 196 days
Bacteremia 3 (17%) 0.026a 12 (48%) 0.000a 0 (0%)
Treatment
Median duration of antibiotics 8 weeks 7 weeks 8 weeks
Use of rifampin 8 (44%) 0.033a 17 (68%) 24 (62%)
Median No. of surgical interventions 2.5 2 0.037a 2
Removal of infected implant 14 (78%) 18 (72%) 30 (77%)
Re-implantation of a new implant 4 (22%) 10 (40%) 22 (56%)
Two-stage revision 4 (100%) 9 (90%) 19 (86%)
Median delay between stages 208 days 69 days 98 days
Outcomes
Recurrence of infection 2 (11%) 5 (20%) 5 (13%)
Cure 7 (39%) 15 (60%) 30 (77%)
Median length of hospital stay 66 days 44 days 51 days
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; CoNS, coagulase-negative staphylococci.
Group comparisons were performed with the Wilcoxon rank sum test, Fisher’s exact test, or the Pearson Chi-square test, as appropriate.
a Only statistically signiﬁcant p-values of 0.05 (two-tailed) are displayed.
b Diabetes mellitus, transplantation, chronic alcoholism, neoplasia, Child’s class C cirrhosis, AIDS, steroid medication.
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duration 52 vs. 24 days, p < 0.001), and weremore likely to receive
a new implant (34/82 vs. 15/81, p = 0.001). In contrast, the
proportions of implant removal were similar (62 vs. 59, p = 0.69).
Table 2 summarizes the characteristics of arthroplasty patients
stratiﬁed by staphylococcal infection. Of note, MRSA infections
occurred at a signiﬁcantly higher patient age, had shorter
incubation times, and beneﬁted less from the use of rifampin.
3.8. Adjustment of risk factors
Table 3 summarizes the univariate and the multivariate results
of logistic regression. In multivariate analysis including all implant
infections, arthroplasty (OR 0.2, 95% CI 0.1–0.6) and MRSA
infections (OR 0.3, 95% CI 0.1–0.9) were signiﬁcantly associated
with lower cure outcomes, whereas CoNS infection (OR 3.0, 95% CI
1.2–8.0) and the insertion of a new implant (OR 4.5, 95% CI 1.6–
13.1) were signiﬁcantly associated with higher cure results.
In the separate analysis for the group of arthroplasty infections
only, a new implant (OR 12.8, 95% CI 2.7–61.9) showed a
statistically signiﬁcant association with cure, while in the group
of fracture ﬁxation device infections, no parameter reached
statistical signiﬁcance.
4. Discussion
Our study shows that clinical features and outcomes differ
considerably in orthopedic implant infections due to MRSA, MSSA,
or CoNS. Overall, cure increased from 57% for MRSA, to 72% for
MSSA, and to 82% for CoNS. This tendency was also similar when
considering arthroplasty infections separately, with corresponding
cure rates of 39%, 60%, and 77%, respectively. In our study, the
overall infection recurrence rate was only 12%, which is less than
reported rates of 26%15 and 38%9 in the literature.
When adjusted in multivariate analysis, revision arthroplasty
with insertion of a new implant (for arthroplasty infections) was
the most signiﬁcant protective factor for cure, followed by CoNSdisease (for all types of infection). In contrast, infection due to
MRSAwas inversely associatedwith cure,9,10 as was the case in the
group of arthroplasty infections compared to the group with
fracture ﬁxation devices, which were mostly removed when
infected. As previously reported by others,15,16 patient demo-
graphics (immunosuppression, sex, age), disease intensity (bac-
teremia), and treatment modalities (rifampin use,17,18 duration of
antibiotic therapy, number of surgical interventions, proportion of
one-stage revisions) did not inﬂuence cure.
One explanation for the lower cure rates of MRSA infections
might lie in the lower proportion of new implants inserted inMRSA
infections as compared to those patients with CoNS disease. This is
highlighted by signiﬁcantly more sequelae for patients with MRSA
infections. Theoretically, a higher sequelae riskmight be a sign that
surgeons did not perform revision surgery and did not put in a new
implant. We cannot completely exclude this decision bias.
It is clear that infection with S. aureus demonstrates an
enhanced virulence. For example bacteremic disease, a hallmark
of S. aureus infection, was not seen in CoNS disease. Two patients in
our study died secondary to S. aureus septicemia. Contrary to the
evidence for staphylococcal bloodstream infections,7,8 non-pros-
thetic surgical site infections,19 and community-acquired MRSA,14
it remains unclear whether staphylococcal methicillin resistance
among S. aureus or CoNS results in failure of treatment in localized
tissue infections. While in vitro studies20 point to this concept, in
vivo studies show conﬂicting results. Al-Nammari et al. reported
the same duration of antimicrobial therapy and the same number
of surgical interventions for the treatment of septic arthritis
whether due to MRSA or MSSA.21 Volin et al. demonstrated that
methicillin resistance did not inﬂuence the probability of cure in
patients with two-stage re-implantation after total joint infec-
tion.22 In contrast, Kilgus et al. showed that infection following hip
arthroplasty secondary to MRSA was treated successfully in only
48% of cases, as compared to 81% with MSSA infection.10 Salgado
et al. attributed a nine-fold higher hazard ratio to treatment failure
in prosthetic joint infections due to MRSA than due to MSSA.9 In
our analysis, methicillin resistance per se was not a risk factor for
Table 3
Predictors of cure in staphylococcal orthopedic implant-associated infections
Univariate analysis Multivariate analysis
OR (95% CI) p-Valuea OR (95% CI) p-Valuea
All implant infections
Female sex 1.5 (0.7–3.0) 2.0 (0.8–4.8)
Age 1.0 (1.0–1.0) 1.0 (1.0–1.0)
MRSA 0.4 (0.2–0.8) 0.011a 0.3 (0.1–0.9) 0.032a
MSSA 1.1 (0.5–2.1) 1.2 (0.5–3.0)
CoNS 2.4 (1.1–5.1) 0.028a 3.0 (1.2–8.0) 0.030a
Total joint arthroplasties 0.4 (0.2–0.9) 0.018a 0.2 (0.1–0.6) 0.002a
Duration of antibiotic treatment 1.0 (0.9–1.0) 0.9 (0.9–1.0)
Number of surgical interventions 1.0 (0.8–1.2) 1.0 (0.8–1.3)
Bacteremic disease 0.5 (0.2–1.1) 0.7 (0.2–2.3)
Methicillin resistanceb 0.6 (0.3–1.2) 1.0 (0.3–3.0)
Total arthroplasties
Female sex 0.9 (0.3–2.1) 1.7 (0.5–5.6)
Age 1.0 (0.9–1.0) 0.9 (0.9–1.0)
MRSA 0.3 (0.1–0.8) 0.018a 0.6 (0.2–2.3)
MSSA 0.8 (0.3–2.1) 1.2 (0.3–5.4)
CoNS 3.2 (1.2–8.3) 0.018a 1.9 (0.5–7.6)
Duration of antibiotic treatment 1.0 (0.9–1.0) 1.0 (0.9–1.2)
Number of surgical interventions 0.8 (0.5–1.2) 0.7 (0.3–1.5)
New implant 8.9 (2.7–29.1) 0.000a 12.8 (2.7–61.9) 0.001a
Bacteremic disease 0.3 (0.1–0.9) 0.048a 0.6 (0.1–6.6)
Methicillin resistanceb 0.7 (0.3–1.8) 1.0 (0.3–3.0)
Non-arthroplasty implants
Female sex 4.5 (1.2–17.2) 0.029a 3.3 (0.7–15.6)
Age 1.0 (1.0–1.0) 1.0 (1.0–1.0)
MRSA 0.4 (0.1–1.2) 0.3 (0.1–1.2)
MSSA 1.2 (0.4–3.7) 1.2 (0.3–5.0)
CoNS 3.1 (0.6–15.0) 5.9 (0.6–58.0)
Duration of antibiotic treatment 0.9 (0.9–1.0) 0.9 (0.8–1.0)
Number of surgical interventions 1.0 (0.8–1.4) 1.0 (0.7–1.5)
Bacteremic disease 0.8 (0.2–3.3) 1.2 (0.2–8.3)
Methicillin resistanceb 0.6 (0.2–1.8) 0.3 (0.1–1.4)
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; CoNS, coagulase-negative staphylococci.
a Only statistically signiﬁcant p-values of 0.05 (two-tailed) are displayed.
b MRSA and methicillin-resistant CoNS.
D. Teterycz et al. / International Journal of Infectious Diseases 14 (2010) e913–e918 e917failure, but was related to a higher age and a longer length of
hospital stay.9 This reﬂects nosocomial aspects rather than damage
by the pathogen itself, because methicillin-resistant infections
more likely occur in the elderly population with more co-
morbidities21 and frequent healthcare contact.4,21
Our study has limitations: (1) It was retrospective, from a single
institution, and with a small sample size, thus limiting the
generalizability of the ﬁndings. (2) Patients with an infection
treated in another hospital may have been undetected. However,
given that the Geneva University Hospitals comprise the largest
and only public hospital in the area, and given the active post-
discharge follow-up of our patients, we consider this selection bias
to be minimal. (3) We used databases with microbiological
documentation, with another possible selection bias for infections
where themicrobiological cultures did not grow any staphylococci.
Half of the infections were due to methicillin-resistant strains,
which are unlikely to bemasked by unreported pre-hospitalization
antibiotic use. In the literature culture-negative prosthetic
infections account for only 7% of cases, and the outcome appears
to be indistinguishable from that due to cultured bacteria.23 (4) The
potential inﬂuence of small-colony variants was not investigated
since it was a retrospective study and many specimens had not
been stored. Small-colony variants are resistant to aminoglyco-
sides, considered difﬁcult to treat, and responsible for recur-
rence.24 However, we consider their inﬂuence to be minimal
because small-colony variants are inherent to all three groups of
staphylococci independent of their methicillin resistance.24,25 In
addition, our episodes were not recurrent infections and patients
were not subjected to long-term anti-staphylococcal therapy
before the onset of their infection.Acknowledgements
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